Medulloblastoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Medulloblastoma Pipeline Drugs Market Report Overview
Medulloblastoma is the most common malignant brain tumor in children. Medulloblastoma by definition occurs in the cerebellum, which is the part of the brain located at the base of the skull, just above the brainstem. Symptoms associated with a Medulloblastoma include headaches in the morning that improve as the day goes on, recurrent vomiting, and difficulty walking and with balance. Medulloblastoma can spread to other areas of the central nervous system. Treatment includes options such as chemotherapy, surgery, biological therapy, and radiation therapy.
The Medulloblastoma drugs in development market research report provides comprehensive information on the therapeutics under development for Medulloblastoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Medulloblastoma and features dormant and discontinued projects.
Medulloblastoma Pipeline Drugs Market Segmentation by Targets
Some of the targets in the Medulloblastoma pipeline are Smoothened Homolog, Cells Expressing CD276 Antigen, Signal Transducer And Activator Of Transcription 3, CD3, Cells Expressing Interleukin 13 Receptor Subunit Alpha 2, and Cyclin Dependent Kinase 4 among others. Smoothened Homolog was the largest target in the pipeline.
Medulloblastoma Pipeline Drugs Market Analysis, by Targets
For more Medulloblastoma pipeline drugs market target insights, download a free report sample
Medulloblastoma Pipeline Drugs Market Segmentation by Mechanisms of Action
Some of the mechanisms of action in the Medulloblastoma pipeline drugs market are Smoothened Homolog Antagonist, Cytotoxic To Cells Expressing CD276 Antigen, Signal Transducer And Activator Of Transcription 3 Inhibitor, CD3 Agonist, and Cyclin Dependent Kinase 4 Inhibitors among others. Smoothened Homolog Antagonist was the leading MoA in the pipeline.
Medulloblastoma Pipeline Drugs Market Analysis, by Mechanisms of Action
For more MoA insights into the Medulloblastoma pipeline drugs market, download a free report sample
Medulloblastoma Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Medulloblastoma pipeline drugs market are oral, intravenous, intratumor, intraperitoneal, and subcutaneous among others. The majority of the pipeline drugs followed the oral route of administration.
Medulloblastoma Pipeline Drugs Market Analysis, by Routes of Administration
For more routes of administration insights into the Medulloblastoma pipeline drugs market, download a free report sample
Medulloblastoma Pipeline Drugs Market Segmentation by Molecule Types
The leading molecule types in the Medulloblastoma pipeline drugs market are small molecule, monoclonal antibody, oncolytic virus, gene-modified cell therapy, and subunit vaccine among others. Small molecule was the leading molecule type in the pipeline.
Medulloblastoma Pipeline Drugs Market Analysis, by Molecule Types
For more molecule type insights into the Medulloblastoma pipeline drugs market, download a free report sample
Medulloblastoma Pipeline Drugs Market - Competitive Landscape
Some of the key companies in the Medulloblastoma pipeline drugs market are Acrivon Therapeutics Inc, Bayer AG, Bristol-Myers Squibb Co, Immunomic Therapeutics Inc, Moleculin Biotech Inc, and Novartis AG. Among these, Moleculin Biotech Inc had the most number of products under development in 2022.
Medulloblastoma Pipeline Drugs Market Analysis by Key Companies
To know more about the Medulloblastoma pipeline drugs market companies, download a free report sample
Medulloblastoma Pipeline Drugs Market Report Overview
Key Targets | Smoothened Homolog, Cells Expressing CD276 Antigen, Signal Transducer and Activator of Transcription 3, CD3, Cells Expressing Interleukin 13 Receptor Subunit Alpha 2, and Cyclin Dependent Kinase 4 |
Key Mechanism of Actions | Smoothened Homolog Antagonist, Cytotoxic to Cells Expressing CD276 Antigen, Signal Transducer and Activator of Transcription 3 Inhibitor, CD3 Agonist, and Cyclin Dependent Kinase 4 Inhibitors |
Key Routes of Administration | Oral, Intravenous, Intratumor, Intraperitoneal, and Subcutaneous |
Key Molecule Types | Small Molecule, Monoclonal Antibody, Oncolytic Virus, Gene-Modified Cell Therapy, and Subunit Vaccine |
Key Companies | Acrivon Therapeutics Inc, Bayer AG, Bristol-Myers Squibb Co, Immunomic Therapeutics Inc, Moleculin Biotech Inc, and Novartis AG |
Scope
- The report provides a snapshot of the global therapeutic landscape of Medulloblastoma
- The report reviews pipeline therapeutics for Medulloblastoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Medulloblastoma therapeutics and enlists all their major and minor projects
- The report assesses Medulloblastoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews the latest news related to pipeline therapeutics for Medulloblastoma
Reasons to Buy
- The report provides a snapshot of the global therapeutic landscape of Medulloblastoma
- The report reviews pipeline therapeutics for Medulloblastoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Medulloblastoma therapeutics and enlists all their major and minor projects
- The report assesses Medulloblastoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews the latest news related to pipeline therapeutics for Medulloblastoma
Aettis Inc
Bayer AG
Biogenera SpA
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Cardiff Oncology Inc
Centessa Pharmaceuticals Plc
Chengdu Jinrui Foundation Biotechnology Co Ltd
Chimerix Inc
Cothera Bioscience Pty Ltd
Curis Inc
Curtana Pharmaceuticals Inc
Dalriada Therapeutics Inc
Dracen Pharmaceuticals Inc
Edison Oncology Holding Corp
Exelixis Inc
Gan & Lee Pharmaceuticals Co Ltd
Gennao Bio Inc
Guangdong Zhongsheng Pharmaceutical Co Ltd
Immunomic Therapeutics Inc
IMPACT Therapeutics Inc
Istari Oncology Inc
Kintor Pharmaceutical Ltd
Lumos Pharma Inc
MacroGenics Inc
Mana Therapeutics Inc
Midatech Pharma Plc
MimiVax LLC
Moleculin Biotech Inc
Mustang Bio Inc
Nanjing KAEDI Biotech Inc
Nascent Biotech Inc
Novartis AG
Nurix Therapeutics Inc
Nuvectis Pharma Inc
Oncoheroes Biosciences Inc
Ono Pharmaceutical Co Ltd
Orphelia Pharma SAS
Oxurion NV
Pfizer Inc
Progenics Pharmaceuticals Inc
Sapience Therapeutics Inc
Senhwa Biosciences Inc
Shionogi & Co Ltd
Stemsynergy Therapeutics Inc
Sun Pharma Advanced Research Company Ltd
VBI Vaccines Inc
Vyriad Inc
Vyro Bio Inc
Wuhan Binhui Biotechnology Co Ltd
Y-mAbs Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the Medulloblastoma pipeline drugs market?
Some of the key targets of the Medulloblastoma pipeline drugs market are Smoothened Homolog, Cells Expressing CD276 Antigen, Signal Transducer And Activator Of Transcription 3, CD3, Cells Expressing Interleukin 13 Receptor Subunit Alpha 2, and Cyclin Dependent Kinase 4 among others.
-
What are the key mechanisms of action in the Medulloblastoma pipeline drugs market?
Some of the key mechanisms of action in the Medulloblastoma pipeline drugs market are Smoothened Homolog Antagonist, Cytotoxic To Cells Expressing CD276 Antigen, Signal Transducer And Activator Of Transcription 3 Inhibitor, CD3 Agonist, and Cyclin Dependent Kinase 4 Inhibitors.
-
What are the key routes of administration in the Medulloblastoma pipeline drugs market?
The key routes of administration in the Medulloblastoma pipeline drugs market are oral, intravenous, intratumor, intraperitoneal, and subcutaneous.
-
What are the key molecule types in the Medulloblastoma pipeline drugs market?
The molecule types in the Medulloblastoma pipeline drugs market are small molecule, monoclonal antibody, oncolytic virus, gene-modified cell therapy, and subunit vaccine.
-
Which are the key companies in the Medulloblastoma pipeline drugs market?
Some of the key companies in the Medulloblastoma pipeline drugs market are Acrivon Therapeutics Inc, Bayer AG, Bristol-Myers Squibb Co, Immunomic Therapeutics Inc, Moleculin Biotech Inc, and Novartis AG.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.